30 avril 2020
Back
Related Posts
XENOTHERA therapeutic farm, unique in France and across Europe, is featured in a major report published by Les Échos Week-End on April 24, 2026
Our 500 animals are raised under exceptional sanitary conditions, with one ambition: paving the way for animal-to-human organ transplantation. The report highlights the concrete challenges of xenotransplantation in France. It also showcases what XENOTHERA, at the heart of the XENOCURE consortium, is already developing today, notably its LIS1 antibody, administered during allografts to neutralize the immune system’s immediate response. It has received orphan drug designation in both the United States and Europe.
Read MoreXENOTHERA strengthens its position in oncology and announces several clinical advances and scientific publications
October, 2025. Nantes-based biotech company XENOTHERA is accelerating its developments in oncology with several multispecific glyco-humanized antibody (GH-pAb) programs. The company today announces new clinical milestones and major publications
Read MoreXENOTHERA confirms progress in the treatment of peripheral T-cell lymphoma (PTCL) through its LIS22 antibody
June, 2025, Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone
Read More